{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:42:59Z","timestamp":1793828579238,"version":"4.6.1"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.atherosclerosis.2022.08.011","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T21:40:59Z","timestamp":1660945259000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification"],"prefix":"10.1016","volume":"357","author":[{"given":"Francesco","family":"Baratta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D'Erasmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angelico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Del Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-6599","authenticated-orcid":false,"given":"Alessia","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.atherosclerosis.2022.08.011_bib1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2022.08.011_bib2","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3350\/cmh.2013.19.2.120","article-title":"Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease","volume":"19","author":"Kim","year":"2013","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2008.06.018","article-title":"Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease","volume":"49","author":"Ong","year":"2008","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.08.011_bib10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(21)00337-X","article-title":"The challenge of cardiovascular prevention in NAFLD","volume":"6","author":"Del Ben","year":"2021","journal-title":"lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/jc.2012-3093","article-title":"Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications","volume":"98","author":"Targher","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.08.011_bib13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib14","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MEG.0000000000001075","article-title":"Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Zhou","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep4.1155","article-title":"Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis","volume":"2","author":"Zhou","year":"2018","journal-title":"Hepatol. Commun."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0041-1730927","article-title":"Insights into nonalcoholic fatty-liver disease heterogeneity","volume":"41","author":"Arrese","year":"2021","journal-title":"Semin. Liver Dis."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib19","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.1840200611","article-title":"Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study","volume":"20","author":"Bellentani","year":"1994","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.08.011_bib20","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/ajg.2017.371","article-title":"Adherence to mediterranean diet and non-alcoholic fatty liver disease: effect on insulin resistance","volume":"112","author":"Baratta","year":"2017","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"Marchesini","year":"1999","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.08.011_bib23","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.08.011_bib24","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1440-1746.2006.04698.x","article-title":"Significant correlations between severe fatty liver and risk factors for metabolic syndrome","volume":"22","author":"Hsiao","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.08.011_bib25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1464-5491.2005.01582.x","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults","volume":"22","author":"Jimba","year":"2005","journal-title":"Diabet. Med."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib26","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib28","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.08.011_bib30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2022.08.011_bib31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2036.2011.04929.x","article-title":"Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease","volume":"35","author":"Petta","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"48","key":"10.1016\/j.atherosclerosis.2022.08.011_bib33","article-title":"Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib34","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10620-021-06953-z","article-title":"Visceral adipose tissue and non-alcoholic fatty liver disease in patients with type 2 diabetes","volume":"67","author":"Nobarani","year":"2022","journal-title":"Dig. Dis. Sci."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cld.1183","article-title":"Nonalcoholic fatty liver disease: the role of visceral adipose tissue","volume":"19","author":"Hanlon","year":"2022","journal-title":"Clin. Liver Dis."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib36","first-page":"189","article-title":"Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease","volume":"56","author":"Abenavoli","year":"2014","journal-title":"Panminerva Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib37","first-page":"12","article-title":"MAFLD and NAFLD: is there the need for redefining the risk of cardiovascular disease and mortality?","volume":"2","author":"Lombardi","year":"2021","journal-title":"Metab. Target. Organ. Damage"},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib38","doi-asserted-by":"crossref","DOI":"10.5009\/gnl210290","article-title":"Fibrotic burden determines cardiovascular risk among subjects with metabolic dysfunction-associated fatty liver disease","author":"Han","year":"2022","journal-title":"Gut. Liver"},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.atherosclerosis.2016.12.018","article-title":"Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically- versus genetically-driven excess fat hepatic storage","volume":"257","author":"Di Costanzo","year":"2017","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-21939-0","article-title":"Evaluation of polygenic determinants of non-alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy","volume":"8","author":"Di Costanzo","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41390-019-0303-1","article-title":"Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity","volume":"85","author":"Di Costanzo","year":"2019","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J. Intern. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib43","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib45","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib46","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib47","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib48","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep4.1192","article-title":"Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease","volume":"2","author":"Dongiovanni","year":"2018","journal-title":"Hepatol. Commun."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.08.011_bib49","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2020.04.021","article-title":"MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans","volume":"73","author":"Luukkonen","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metabol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15943-z","article-title":"PNPLA3 variant and portal\/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress","volume":"7","author":"Carpino","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.08.011_bib54","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine (Baltim.)"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2022.08.011_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18178993","article-title":"Open issues in the transition from NAFLD to MAFLD: the experience of the Plinio study","volume":"18","author":"Baratta","year":"2021","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/gutjnl-2020-322564","article-title":"Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?","volume":"71","author":"Younes","year":"2022","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.08.011_bib58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/biomedicines8120625","article-title":"HDL-mediated cholesterol efflux and plasma loading capacities are altered in subjects with metabolically- but not genetically driven non-alcoholic fatty liver disease (NAFLD)","volume":"8","author":"Di Costanzo","year":"2020","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279 013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib60","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib61","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng.2926","article-title":"Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk","volume":"46","author":"Holmen","year":"2014","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib62","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2020","journal-title":"Diabetologia"},{"issue":"7121","key":"10.1016\/j.atherosclerosis.2022.08.011_bib64","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nature05487","article-title":"Mechanisms linking obesity with cardiovascular disease","volume":"444","author":"Van Gaal","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib65","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11892-008-0011-4","article-title":"Fatty liver, insulin resistance, and dyslipidemia","volume":"8","author":"Adiels","year":"2008","journal-title":"Curr. Diabetes Rep."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib66","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","article-title":"Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile","volume":"13","author":"Siddiqui","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib67","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cyto.2018.05.030","article-title":"Serum Angiopoietin-like peptide 4 levels in patients with hepatic steatosis","volume":"111","author":"Altun","year":"2018","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22020742","article-title":"The interplay between angiopoietin-like proteins and adipose tissue: another piece of the relationship between adiposopathy and cardiometabolic diseases?","volume":"22","author":"Bini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib69","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/biom12040585","article-title":"The fibrinogen-like domain of ANGPTL3 facilitates lipolysis in 3T3-L1 cells by activating the intracellular erk pathway","volume":"12","author":"Bini","year":"2022","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0193731","article-title":"Association of circulating ANGPTL 3,4, and 8 levels with medical status in a population undergoing routine medical checkups: a cross-sectional study","volume":"13","author":"Morinaga","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.08.011_bib71","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2337\/dc06-0455","article-title":"Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes","volume":"29","author":"Toledo","year":"2006","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2022.08.011_bib72","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehaa172","article-title":"Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: mendelian randomization in the Copenhagen General Population Study","volume":"41","author":"Kaltoft","year":"2020","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.08.011_bib73","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1194\/jlr.RA120000746","article-title":"Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease","volume":"61","author":"Cao","year":"2020","journal-title":"J. Lipid Res."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.08.011_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7110378","article-title":"Remnant lipoprotein cholesterol and cardiovascular and cerebrovascular events in patients with non-alcoholic fatty liver disease","volume":"7","author":"Pastori","year":"2018","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib75","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/EJE-20-1240","article-title":"Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study","volume":"184","author":"Juli\u00e1n","year":"2021","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib76","doi-asserted-by":"crossref","first-page":"796","DOI":"10.5114\/aoms.2011.25554","article-title":"Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study","volume":"7","author":"Athyros","year":"2011","journal-title":"Arch. Med. Sci."},{"issue":"9756","key":"10.1016\/j.atherosclerosis.2022.08.011_bib77","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib78","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD","volume":"101","author":"Bril","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib79","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","article-title":"Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance","volume":"52","author":"Garvey","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metabol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.08.011_bib81","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1210\/jc.2007-0187","article-title":"Postprandial lipemia associates with liver fat content","volume":"92","author":"Matikainen","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib82","doi-asserted-by":"crossref","DOI":"10.1186\/s12950-019-0211-5","article-title":"Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease","volume":"16","author":"Ho","year":"2019","journal-title":"J. Inflamm."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.08.011_bib83","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1185\/03007995.2014.909394","article-title":"Postprandial lipemia as a cardiometabolic risk factor","volume":"30","author":"Pirillo","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.08.011_bib84","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s11745-001-0822-5","article-title":"Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients","volume":"36","author":"Cassader","year":"2001","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib85","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1586\/17474124.2016.1110018","article-title":"The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?","volume":"10","author":"Dongiovanni","year":"2016","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib86","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib87","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib88","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.08.011_bib89","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1074\/jbc.M010029200","article-title":"Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver","volume":"276","author":"Koo","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib90","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOL.0000000000000155","article-title":"Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism","volume":"26","author":"Raimondo","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib91","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/liv.13994","article-title":"Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis","volume":"39","author":"Morrison","year":"2019","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib93","first-page":"372","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","author":"Palmer","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1060028020935105","article-title":"A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib95","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/oby.2008.64","article-title":"NASH predicts plasma inflammatory biomarkers independently of visceral fat in men","volume":"16","author":"Targher","year":"2008","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib96","article-title":"Endothelial dysfunction and cardiovascular disease","volume":"2014","author":"Widmer","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib97","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2214\/ajr.166.1.8571908","article-title":"Endothelial cell function: biologic and physiologic functions in health and disease","volume":"166","author":"Shireman","year":"1996","journal-title":"AJR Am. J. Roentgenol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2022.08.011_bib98","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3390\/biomedicines9070781","article-title":"Inflammatory mechanisms contributing to endothelial dysfunction","volume":"9","author":"Theofilis","year":"2021","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.08.011_bib99","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib100","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1825142","article-title":"Endothelial dysfunction, a marker of atherosclerosis, is independent of metabolic syndrome in NAFLD patients","volume":"2020","author":"Narayan","year":"2020","journal-title":"Int J Hepatol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2022.08.011_bib101","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.dld.2016.04.004","article-title":"Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients","volume":"48","author":"Gentili","year":"2016","journal-title":"Dig. Liver Dis."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.numecd.2017.10.027","article-title":"Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis","volume":"28","author":"Loffredo","year":"2017","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.08.011_bib103","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.amjcard.2015.02.032","article-title":"Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors","volume":"115","author":"Pastori","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib104","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4274\/Jcrpe.891","article-title":"Relationship between aspartate aminotransferase-to-platelet ratio index and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease","volume":"5","author":"Sert","year":"2013","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpeds.2021.01.019","article-title":"Elevated serum concentrations of remnant cholesterol associate with increased carotid intima-media thickness in children and adolescents","volume":"232","author":"Di Costanzo","year":"2021","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib106","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/01.ATV.0000160613.57985.18","article-title":"Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study","volume":"25","author":"Brea","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.08.011_bib107","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4254\/wjh.v7.i10.1325","article-title":"Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis","volume":"7","author":"Polimeni","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib108","first-page":"2762","article-title":"New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress","volume":"12","author":"Ferro","year":"2020","journal-title":"Nutr"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib109","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-14-81","article-title":"NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease","volume":"14","author":"Del Ben","year":"2014","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/ATVBAHA.112.300438","article-title":"Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress","volume":"33","author":"Violi","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.08.011_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.43","article-title":"Similar reduction of cholesterol-adjusted Vitamin E serum levels in simple steatosis and non-alcoholic steatohepatitis","volume":"6","author":"Pastori","year":"2015","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib112","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib113","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00900-1","article-title":"The gut microbiome in atherosclerotic cardiovascular disease","volume":"8","author":"Jie","year":"2017","journal-title":"Nat. Commun."},{"issue":"43","key":"10.1016\/j.atherosclerosis.2022.08.011_bib114","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib115","article-title":"Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients","volume":"8","author":"Cui","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib116","first-page":"219","article-title":"Effects of lipid based Multiple Micronutrients Supplement on the birth outcome of underweight pre-eclamptic women: a randomized clinical trial","volume":"38","author":"Mohammad","year":"2022","journal-title":"Pakistan J. Med. Sci."},{"issue":"7341","key":"10.1016\/j.atherosclerosis.2022.08.011_bib117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib118","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11739-020-02470-5","article-title":"TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Guasti","year":"2021","journal-title":"Intern. Emerg. Med."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2022.08.011_bib119","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1089\/ars.2016.6963","article-title":"Atherothrombosis and oxidative stress: mechanisms and management in elderly","volume":"27","author":"Violi","year":"2017","journal-title":"Antioxidants Redox Signal."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2022.08.011_bib120","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.116.025338","article-title":"Gut microbe-generated trimethylamine N-oxide from dietary choline is prothrombotic in subjects","volume":"135","author":"Zhu","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.07.010","article-title":"Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes","volume":"47","author":"Le\u00f3n-Mimila","year":"2021","journal-title":"Diabetes Metab."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2022.08.011_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900257","article-title":"Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease","volume":"63","author":"Tan","year":"2019","journal-title":"Mol. Nutr. Food Res."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib123","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12072-010-9219-x","article-title":"The role of lipopolysaccharide\/toll-like receptor 4 signaling in chronic liver diseases","volume":"4","author":"Soares","year":"2010","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2021.11.019","article-title":"Toll-like receptor 4 activation in platelets from myocardial infarction patients","volume":"209","author":"Barill\u00e0","year":"2022","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22076-4","article-title":"Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque","volume":"8","author":"Carnevale","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib126","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib127","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.mayocp.2020.06.057","article-title":"Long-term risk of major adverse cardiac events in atrial fibrillation patients on direct oral anticoagulants","volume":"96","author":"Pastori","year":"2021","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.08.011_bib129","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1194\/jlr.P900013-JLR200","article-title":"A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity","volume":"50","author":"Sookoian","year":"2009","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib130","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/hep.23768","article-title":"PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease","volume":"52","author":"Speliotes","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib131","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jhep.2010.10.042","article-title":"Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease","volume":"55","author":"Krawczyk","year":"2011","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2022.08.011_bib132","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.dld.2012.05.006","article-title":"PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals","volume":"44","author":"Burza","year":"2012","journal-title":"Dig. Liver Dis."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2022.08.011_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074089","article-title":"PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease","volume":"8","author":"Petta","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib134","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1194\/jlr.M048777","article-title":"The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis","volume":"56","author":"Shen","year":"2015","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.011_bib136","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/jgh.12889","article-title":"PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis","volume":"30","author":"Zhang","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2022.08.011_bib137","article-title":"Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis","volume":"5","author":"Xu","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.011_bib138","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2016.12.020","article-title":"PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease","volume":"152","author":"Simons","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib139","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1194\/jlr.P067454","article-title":"Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study","volume":"58","author":"Krawczyk","year":"2017","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.011_bib140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ijc.31910","article-title":"PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases","volume":"144","author":"Yang","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.011_bib141","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-020-01207-9","article-title":"Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease","volume":"19","author":"Wu","year":"2020","journal-title":"Lipids Health Dis."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.011_bib142","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.28142","article-title":"The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis","volume":"62","author":"Pirola","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.011_bib143","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jhep.2020.03.032","article-title":"Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis","volume":"73","author":"Parisinos","year":"2020","journal-title":"J. Hepatol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022013946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022013946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:50:32Z","timestamp":1758156632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022013946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":143,"alternative-id":["S0021915022013946"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.08.011","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}